Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Ipilimumab 17Nivolumab 15incomplete Freund's adjuvant 8Cyclophosphamide 7CTLA-4 Antigen 7pembrolizumab 6Ranibizumab 6sargramostim 5Radiosurgery 5Blood Specimen Collection 5tebentafusp 4Temozolomide 4Surveys and Questionnaires 4Magnetic Resonance Spectroscopy 4MART-1 Antigen 4Granulocyte-Macrophage Colony-Stimulating Factor 4Biopsy 4Bevacizumab 4fludarabine phosphate 3fludarabine 3aflibercept 3Thalidomide 3Sunitinib 3Specimen Handling 3MAGEA3 protein, human 3Interleukin-2 3130-nm albumin-bound paclitaxel 3relatlimab 2olaparib 2montanide ISA 51 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Uveal Melanoma × NSC 366140 × Clear all
NCT00003802 2012-12-17

Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡